Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
An Open-label, Dose-escalation, Phase 1 Trial to Investigate the Safety, Tolerability, and Efficacy After Single- and Multiple-dose Administration of CT303 in Patients With Moderate to Severe Plaque Psoriasis
Sponsor: GC Cell Corporation
This PHASE1 trial investigates Moderate to Severe Plaque Psoriasis and is currently ongoing. GC Cell Corporation leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1
-
Feb 2025 — Sep 2025 [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Apr 2022 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GC Cell Corporation
For direct contact, visit the study record on ClinicalTrials.gov .